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Objective: The Global Assessment of Severity of Epilepsy (GASE) Scale is a singleitem, 7-point global rating scale designed for neurologist-report of overall severity of
epilepsy in children. Building on previous preliminary evidence of its validity and reliability for research and clinical use, this study evaluated the GASE Scale’s construct
validity, reliability, and responsiveness to changes in severity of epilepsy.
Methods: Data used for the study arose from the Health-Related Quality of Life in Children with Epilepsy Study (HERQULES), a 2-year multicenter prospective cohort study
(n = 374) with observations taken at baseline, and 6, 12, and 24 months after diagnosis.
Construct validity and reliability were quantified using Spearman’s correlation and
intraclass correlation coefficient (ICC). Responsiveness was assessed using both distribution-based and anchor-based indices.
Results: The GASE Scale was at least moderately correlated (r ≥ 0.30) with several
key clinical aspects and most strongly correlated with frequency and intensity of seizures and interference of epilepsy or drugs with daily activities (r > 0.30). Total variation in GASE Scale scores explained by seven core clinical aspects of epilepsy increased
over time (R2 = 28% at baseline to R2 = 70% at 24 months). The GASE Scale had modest test–retest reliability (ICC range: 0.52–0.64) and was responsive to changes in clinical criteria (standardized response mean range: 0.49–0.68; probability of change
range: 0.69–0.75; Guyatt’s responsiveness statistic range: 0.56–0.84). The GASE Scale
showed potential to discriminate “stable” and “changed” patients according to select
criteria and to a composite score (area under the receiver operating characteristic
[ROC] curve range: 0.50–0.67).
Significance: Results offer additional evidence in support of the GASE Scale’s validity,
reliability, as well as responsiveness to changes in severity of epilepsy in children. We
conclude that the GASE Scale is a potentially useful tool for assessing the severity of
epilepsy in both clinical and research settings.
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The severity of epilepsy has been assessed predominantly
with measures of the severity of seizures. These measures
fail to address other dimensions of epilepsy such as disability caused by disease and side effects of antiepileptic drugs
(AEDs). Most existing scales are limited by the difficulty of
use and inadequate evidence supporting validity, reliability,
and responsiveness to change.1 The International League
Against Epilepsy (ILAE) has emphasized the importance of
broader assessment tools to better capture the severity of
epilepsy.2
The Global Assessment of Severity of Epilepsy
(GASE) Scale is a single-item, 7-point global rating
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tion of the diagnosis of epilepsy previously. Details of
HERQULES have been described previously.4

Key Points
•
•
•
•
•

GASE Scale captured important clinical aspects in
assessing overall severity of epilepsy in >300 children
with newly diagnosed epilepsy
GASE Scale’s validity is supported by moderate/
strong correlations with clinical aspects, with seizure
frequency/intensity and interference being strongest
Both distribution-based and anchor-based methods
provided evidence that GASE Scale detected withinpatient changes in severity of epilepsy
GASE Scale showed potential to discriminate “stable”
and “changed” patients according to select clinical criteria and to a composite score
Further research is needed to define meaningful stability and change for clinical criteria and the GASE Scale

scale. It was developed as a clinician-report measure to
assess the overall severity of epilepsy in children and to
provide a simple and efficient tool to capture the multidimensional nature of epilepsy. Previous research provided
preliminary evidence to support the GASE Scale’s content and convergent validity, inter-rater and test–retest
reliability, and discriminative properties for three types
of epilepsy syndromes using a clinical case scenario
method.3 The purpose of this study was to further assess
the measurement properties of the GASE Scale when
applied by neurologists to assess patients in their care
using data from a large prospective cohort study. Specifically, we assessed the GASE Scale’s construct validity,
reliability, and responsiveness to change in the severity
of epilepsy.
We hypothesized that the GASE Scale would have at
least a moderate degree of construct validity and test–retest
reliability, and be sensitive to changes in the severity of epilepsy.

Methods
Data source and study sample
The Health-Related Quality of Life in Children with Epilepsy Study (HERQULES) provided the data for this study.
HERQULES is a 2-year prospective cohort study assessing
the course and determinants of health-related quality of life
(HRQL) in children with new onset epilepsy across
Canada.4 Using a two-stage clustered sampling strategy
between April 2004 and April 2007, 53 (74%) of practicing
pediatric neurologists in Canada recruited parents of children with epilepsy (median: nine families per physician).
The sample included children ages 4–12 years with ≥2
unprovoked seizures. The children were seeing a pediatric
neurologist for the first time and had not received confirma-

Measures
At baseline, and at 6, 12, and 24 months following the
diagnosis of epilepsy, a questionnaire collected parent-report of their children’s HRQL and a series of child and family characteristics, while a physician-report form collected
information on clinical characteristics of the child’s epilepsy. HRQL was measured using the Quality of Life in
Childhood Epilepsy Questionnaire (QOLCE)5 and the Child
Health Questionnaire (CHQ).6
Parent report
Parents’ responses to two questions contained in the
QOLCE were used to represent parents’ perceptions of their
child’s health. The first question asked: “Compared to other
children his/her age, how do you think your child’s health
has been in the past 4 weeks? Please consider your child’s
epilepsy as part of his/her health when you answer this question.” Response options were: 1 = “Poor”; 2 = “Fair”;
3 = “Good”; 4 = “Very good”; and 5 = “Excellent.” The
second question asked: “Compared to 1 year ago, how
would you rate your child’s health now?” Response options
were: 1 = “Much better now than 1 year ago”; 2 = “Somewhat better now than 1 year ago”; 3 = “About the same
now as 1 year ago”; 4 = “Somewhat worse now than 1 year
ago”; and 5 = “Much worse now than 1 year ago.”
Physician report
The GASE Scale asked physicians to rate the overall
severity of each child’s epilepsy at the time of clinical
assessment.3 It is a single-item, 7-point Likert scale that
asks: “Taking into account all aspects of this patient’s epilepsy, how would you rate its severity at his/her last visit?
Please check one answer.” Response options are 1 = “Not
at all severe”; 2 = “A little severe”; 3 = “Somewhat severe”; 4 = “Moderately severe”; 5 = “Quite severe”;
6 = “Very severe”; 7 = “Extremely severe.”
Physicians also documented the following seven core
clinical aspects (selected by an expert clinical panel)3 of each
patient’s epilepsy: frequency of seizures, intensity of
seizures, falls or injuries during seizures, severity of the
postictal period, amount of AEDs (denoting the combination
of number and dosage), side effects of AEDs, and interference of epilepsy or drugs with daily activities. These aspects
were rated on a 7-point Likert scale with 1 = “none or never”
and 7 = “extremely frequent, severe, or high.” As additional
indicators of severity, physicians also recorded the occurrence of convulsive status epilepticus, whether seizures were
exclusively nocturnal, and the number of AEDs currently.
Analysis
Construct validity was assessed by measuring the correlation of GASE Scale scores with neurologists’ ratings of
Epilepsia, 56(12):1950–1956, 2015
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clinical characteristics of epilepsy and with parents’ perceptions of their child’s health at baseline, and at 6, 12, and
24 months postdiagnosis. We used Spearman rank-correlation coefficient; values of 0.10–0.30 were regarded as weak;
0.30–0.50 as moderate; and >0.50 as strong correlations.7
Multiple linear regression was used to assess the specific
relationship between GASE Scale scores and the seven core
clinical aspects of epilepsy, while adjusting for the effects
of the other aspects. R2 from multiple regression analyses
(with 95% confidence interval [CI]) assessed the proportion
of total variation in GASE Scale scores explained by the
seven core clinical aspects of epilepsy.
Test–retest reliability was assessed on the basis of seven
clinical criteria informed by clinical experts: frequency of
seizures, intensity of seizures, falls or injuries during seizures, severity of the postictal period, convulsive status
epilepticus, exclusively nocturnal seizures, and number of
AEDs currently; as well as a composite score of these items
and the parents’ perceptions of their child’s health. We
chose the 6–12 month postdiagnosis interval to assess test–
retest reliability because this 6-month interval is when
patients were most likely to be clinically stable.8 Patients
were classified as “stable” on the clinical criteria if there
was zero change from 6 to 12 months and “changed” if
scores were different during this time period.
Test–retest reliability was quantified using intraclass correlation coefficient (ICC) with 95% CI, and paired t-test calculated for GASE Scale scores from 6 to 12 months
postdiagnosis for each “stable” subsample. An estimated
ICC value for reliability of measurements over time9 above
0.7 was regarded as adequate reliability.8,10 The paired t-test
was additionally used to test the difference in mean GASE
Scale scores at 6 and 12 months postdiagnosis for the stable
subgroup.
Responsiveness was assessed using both distributionbased and anchor-based methods. The standardized
response mean was used to assess internal responsiveness.11
Specifically, at each time point compared to baseline, the
mean change in GASE Scale score was divided by the standard deviation of the respective change in scores.12 To interpret the standardized response mean, the probability of
change statistic was also calculated based on the cumulative
normal distribution. Probability of change ranges between
0.5 (no ability to detect change) and 1.0 (perfect ability). A
probability of change >0.5 suggests that the scale is able to
detect changes.11
For the anchor-based analysis, we used as external criteria the change scores between baseline and 12 months postdiagnosis in the seven clinical aspects of epilepsy used to
assess reliability, their composite score, the parents’ perceptions of their child’s health, and the GASE Scale. This period of time was expected to show the largest change in the
study patients. Only 12 months postdiagnosis was used for
the second question assessing parents’ perceptions of
change in their child’s health, which uses a global rating of
Epilepsia, 56(12):1950–1956, 2015
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change over the previous year. Patients were classified as
“stable” or “changed” as described earlier. For each “changed” subgroup, Guyatt’s responsiveness statistic was calculated for GASE Scale scores and interpreted using Cohen’s
conventions for effect size as small (0.2); moderate (0.5);
and large (0.8).7 The area under the receiver operating characteristic (ROC) curve and 95% CI were used to assess the
ability of GASE Scale change scores to discriminate
between “stable” and “changed” patients with an area under
the ROC curve of 0.50–0.70 classified as low; 0.70–0.90 as
moderate; and >0.90 as high.8 All statistical analyses were
conducted using SAS Version 9.3 (SAS Institute Inc., Cary,
NC, U). Statistical tests were two-sided and performed at
the 0.05 level of significance.

Results
Patient characteristics
Of 456 parents, 374 (82%) completed the baseline questionnaire and 283 (62%) completed all four. Compared with
those who completed the study (n = 283), children who
were lost to follow-up (n = 91) were not significantly different (p > 0.05) in mean age, sex, severity of epilepsy,
behavior problems, or levels of HRQL. However, parents
returning all questionnaires were more likely to be older,
married, and have higher education and income. Complete
patient characteristics have been described previously.4
At baseline, the mean age of children was 7.5 (SD 2.3)
years, and 52% were male. The majority of children were
initially diagnosed with less severe types of epilepsy syndromes, specifically 38.5% with generalized epilepsies,
39.6% with localization-related (partial/focal epilepsies),
20.0% with partial/focal onset and secondary generalization, and 1.9% not determined as focal or generalized. The
mean GASE Scale score was 2.57 (SD 1.19) (between “a little severe” and “somewhat severe” epilepsy). By
24 months, the mean GASE Scale score had decreased to
1.7 (SD 1.06).
Construct validity
Table 1 summarizes the association between GASE
Scale scores and seven clinical aspects of epilepsy. All correlations were statistically significant at p = 0.05, except
for amount of AEDs at baseline (p = 0.20). In most cases,
the seven clinical aspects were moderately correlated with
the GASE Scale. The strength of the correlations increased
over time for all clinical variables. At every time point, three
clinical aspects consistently showed the highest correlations
with the GASE Scale: frequency of seizures, intensity of seizures, and interference of epilepsy or drugs with daily activities. The clinical variables showing the highest correlation
with GASE Scale scores varied over time, that is, intensity
of seizures at baseline, frequency of seizures at 6 months,
and both frequency of seizures and interference with daily
life at 12 and 24 months postdiagnosis. In the multiple lin-

1953
GASE Scale: Measurement Properties
Table 1. Spearman rank correlations of GASE Scale scores with seven clinical aspects of epilepsy assessed by
neurologists at baseline, and 6, 12, and 24 months postdiagnosis
Clinical aspects of epilepsy

Baseline

6 Months

12 Months

24 Months

Spearman Rho
95% CI
p-Value
Spearman Rho
95% CI
p-Value
Spearman Rho
95% CI
p-Value
Spearman Rho
95% CI
p-Value

Frequency
of seizures

Intensity
of seizures

Side effects
of AEDs

Interference of
epilepsy or drugs
with daily activities

Falls or injuries
during seizures

Severity of the
postictal period

Amount
of AEDs

0.30
0.21, 0.39
<0.0001
0.51
0.42, 0.58
<0.0001
0.49
0.40, 0.57
<0.0001
0.60
0.53, 0.67
<0.0001

0.33
0.23, 0.42
<0.0001
0.45
0.36, 0.53
<0.0001
0.48
0.36, 0.53
<0.0001
0.58
0.50, 0.64
<0.0001

0.13
0.03, 0.23
0.0128
0.30
0.20, 0.40
<0.0001
0.38
0.29, 0.47
<0.0001
0.46
0.37, 0.54
<0.0001

0.34
0.25, 0.43
<0.0001
0.47
0.39, 0.55
<0.0001
0.49
0.41, 0.57
<0.0001
0.60
0.52, 0.66
<0.0001

0.30
0.20, 0.39
<0.0001
0.28
0.18, 0.38
<0.0001
0.31
0.21, 0.40
<0.0001
0.42
0.32, 0.50
<0.0001

0.14
0.04, 0.24
0.007
0.24
0.14, 0.34
<0.0001
0.24
0.14, 0.34
<0.0001
0.37
0.27, 0.46
<0.0001

0.07
0.04 to 0.17
0.20
0.28
0.17 to 0.37
<0.0001
0.23
0.13 to 0.33
<0.0001
0.38
0.28 to 0.47
<0.0001

ear regression analysis, the adjusted R2 for the seven clinical
aspects increased over time (from 28% at baseline to 70% at
24 months) (Table 2). Intensity of seizures explained the
most variation in GASE Scale scores at baseline but at 6, 12,
and 24 months, the frequency of seizures and interference
of epilepsy or drugs with daily activities accounted for the
most variance when all clinical aspects were included in the
model.
GASE Scale scores were weakly associated with the parents’ perception of poorer child health at baseline
(r = 0.17; 95% CI 0.27 to 0.07; p = 0.0013) and
6 months (r = 0.23; 95% CI 0.33 to 0.12; p < 0.001).
However, correlations increased to moderate at 12 months
(r = 0.31; 95% CI 0.41 to 0.20; p < 0.001) and

24 months (r =
p < 0.001).

0.34; 95% CI

0.45 to

0.23;

Test–retest reliability
As predicted, the majority of GASE Scale scores (48.8–
73.3%) did not change in patients for whom neurologists
reported stability in the key clinical aspects of epilepsy and
the composite score (Table 3). Although GASE Scale
change scores varied as much as 4 points from 6 to
12 months, the changes were close to zero, and few patients
had larger changes.
For all external criteria, the ICC ranged between 0.52 and
0.64 (Table 3). Relative to other clinical aspects, frequency
of seizures was most strongly related to physicians’ overall

Table 2. Multiple-linear regression analysis showing the coefficient of determination for each model (R2) of the crosssectional association between GASE Scale scores and seven clinical aspects of epilepsy at baseline, and 6, 12, and
24 months postdiagnosis
Regression coefficients
Baseline
Intercept
Frequency of seizures
Intensity of seizures
Falls or injuries during seizures
Severity of the postictal period
Amount of AEDs
Side effects of AEDs
Interference of epilepsy or drugs
with daily activities
R2
Adjusted R2
95% CI for R2
n
Missing

0.90*
0.10*
0.24*
0.15*
0.07
0.09
0.17*
0.23*
0.28*
0.27*
0.19, 0.35
345
42

6 Months
0.42*
0.28*
0.17*
0.07
0.10
0.13*
0.10
0.24*
0.43*
0.42*
0.34, 0.50
338
49

12 Months
0.41*
0.35*
0.03
0.24*
0.17
0.01
0.25*
0.26*

24 Months
0.01
0.47*
0.12
0.14
0.22*
0.07
0.11*
0.42*

0.44*
0.43*
0.34, 0.51
332
55

0.70*
0.69*
0.63, 0.75
321
66

*

Statistically significant at p < 0.05.
Epilepsia, 56(12):1950–1956, 2015
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Table 3. Test–retest reliability (ICC and t-test) for GASE Scale scores from 6 to 12 months postdiagnosis among
“stable” patients (see text for description)
External clinical indicator

ICC (95% CI)

Frequency of seizures
Intensity of seizures
Falls or injuries during seizures
Severity of postictal period
Convulsive status epilepticus
(no at both times)
Exclusively nocturnal seizures
Number of AEDs currently
Composite score
a
Frequency + Intensity + Falls
+ Postictal + CSE + ENS + AEDs

t-test
=
=
=
=
=

n

No change in GASE Scale scores n (%)

0.64 (0.54 to 0.72)
0.60 (0.50 to 0.69)
0.53 (0.44 to 0.61)
0.54 (0.43 to 0.63)
0.52 (0.43 to 0.59)

2.43 (p
0.62 (p
1.64 (p
2.03 (p
2.27 (p

0.02)
0.54)
0.10)
0.04)
0.02)

176
170
252
203
295

118 (67.0)
110 (64.7)
140 (55.6)
120 (59.1)
144 (48.8)

0.55 (0.46 to 0.62)
0.53 (0.42 to 0.60)

2.40 (p = 0.02)
2.40 (p = 0.02)

292
268

148 (50.7)
139 (52.0)

0.61 (0.47 to 0.72)

1.42 (p = 0.16)

101

82 (72.6)

a
Frequency, frequency of seizures; Intensity, intensity of seizures; Falls, falls or injuries during seizures; Postictal, severity of the postictal period; CSE, convulsive
status epilepticus; ENS, exclusive nocturnal seizures; AEDs, number of AEDs currently used.

assessment of stability in the GASE Scale scores, whereas
convulsive status epilepticus was the least related. Results
of the paired t-test showed evidence of stable GASE Scale
scores (no significant difference p > 0.05) only for the subgroups classified as stable based on intensity of seizures,
falls or injuries during seizures, and the composite score.
For children who were “stable” according to the parents’
perception, the ICC for GASE Scale scores was 0.53 (95%
CI 0.38–0.65) with t = 1.7 (p > 0.05).
Responsiveness to change
Distribution-based methods
For comparisons of all three subsequent time points with
baseline, the standardized response means showed a moderate magnitude of change and the corresponding probability
of change was >0.5, and it increased with comparisons at
longer intervals (0.69 for 6 months to baseline, 0.72 for
12 months to baseline, and 0.75 for 24 months to baseline)
(Table 4).
Anchor-based methods
There was a moderate correlation between change in
mean GASE Scale scores from baseline to 12 months and
change in the composite score, intensity and frequency of

Table 4. Responsiveness indices, standardized response
mean, and probability of change statistic for the GASE
Scale scores at baseline compared with 6, 12, and
24 months postdiagnosis
GASE Scale change
score
6 Months – baseline
12 Months – baseline
24 Months – baseline

Standardized
response mean (95% CI)
0.49 ( 0.61 to 0.37)
0.58 ( 0.71 to 0.45)
0.68 ( 0.81 to 0.55)

Epilepsia, 56(12):1950–1956, 2015
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Probability of
change (95% CI)
0.69 (0.65 to 0.73)
0.72 (0.68 to 0.76)
0.75 (0.71 to 0.79)

seizures, and severity of the postictal period over the same
time period, ranging from 0.33 to 0.47. Change in GASE
Scale scores from baseline to 12 months were only weakly
associated with increases in falls or injuries during seizures
and with the parents’ perception of a decline in their child’s
health.
For all “changed” patients (based on clinical aspects and
the composite score), GASE Scale scores from baseline to
12 months demonstrated a moderate to large magnitude of
change (Guyatt’s responsiveness statistic range: 0.56–0.84)
(Table S1). The Guyatt’s responsiveness statistic was highest for patients who “changed” in frequency and intensity of
seizures (Guyatt’s responsiveness statistic = 0.84). GASE
Scale scores also demonstrated a moderate to large magnitude of change when parents reported a change in their
child’s health (Guyatt’s responsiveness statistic range:
0.61–0.70).
The area under the ROC curve ranged from 0.50 to 0.67
for clinical aspects and parents’ perception of change. It was
highest for frequency of seizures, followed by the intensity
of seizures and severity of the postictal period.

Discussion
We found that the GASE Scale captured several important clinical aspects of overall severity of epilepsy in a sample of >300 children across Canada with newly diagnosed
epilepsy, and provide further evidence for its measurement
properties.
Construct validity of the GASE Scale is supported by at
least moderate correlations with the majority of key clinical
aspects. Frequency and intensity of seizures and interference of epilepsy or AEDs with daily activities contributed
most strongly to the physician’s assessment of epilepsy
severity using the GASE Scale. This is consistent with preliminary findings of the relationship between GASE Scale
scores and physician-rated clinical aspects,3 and with
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preliminary reports of moderate correlations between
GASE Scale scores and frequency of seizures in adult
patients with epilepsy.13 The increasing strength in correlations between the GASE Scale and clinical parameters over
time deserves further study. Plausible explanations include
uncertainty at the time of diagnosis, and the effect of
increasing familiarity with the patient’s condition and
response to medications. In addition, physician-rated
assessments of clinical aspects and GASE Scale at baseline
are primarily based on free historical recall from parents
rather than on direct clinical observation. By 6 months,
there may have been greater clarity to aid diagnosis and a
more coherent assessment of severity. Some components of
epilepsy severity become important only after the initial
visit. For example, side effects of AEDs will have relatively
less impact on severity at the time of diagnosis if physicians
have not yet prescribed medication. It is also possible that as
the epilepsy syndrome and type of seizures became clearer
over time, the clinical features pertaining to each syndrome
had a more stable and stronger influence on the overall
assessment of severity in the clinician’s mind.
Parents’ perceptions of their child’s health did not correlate strongly at every time point with the physician’s assessment of severity of epilepsy. This may be because parents
and physicians perceive the child’s epilepsy differently14 or
because they were asked to rate different constructs.
Although parents were asked a question with specific
instruction to rate their child’s health compared to other
children his or her age and in doing so to consider their
child’s epilepsy as part of his/her health, physicians were
asked to rate severity of epilepsy specifically, without any
instruction to compare with a reference population. The
increase in correlation over time may be attributed to physicians and parents sharing their unique expertise and experience with each other, thereby influencing their own
understanding of the child’s epilepsy.14
Although the results showed that GASE Scale scores did
not completely remain stable when key clinical aspects of
epilepsy indicated stability over a 6-month period, most
patients changed by only one point on the GASE Scale from
6 to 12 months postdiagnosis. For stability according to the
parents’ perceptions, GASE Scale scores at the two time
points also did not differ significantly, providing some evidence of the stability of GASE Scale scores over the 6month period. This suggests that using “zero change” to
define stability may have been over-restrictive and underrepresentative of clinical situations assessed with a singleitem scale. A broader definition of stability may be more
meaningful and may provide a more realistic interpretation
of the reliability of the GASE Scale.
Several factors may have contributed to decreased test–
retest reliability. The long interval for the current assessment of stability was limited by the data collection schedule
of HERQULES, where the shortest interval was 6 months
and longer than the typical interval recommended for

assessing test–retest reliability. During this time, patients
with newly diagnosed epilepsy may have experienced
changes in therapy and health. Another reason could be the
method used for classifying patients as stable according to
individual clinical variables. Although reliability was
higher when patients were classified by the composite score,
the GASE Scale was designed to encompass all aspects of
epilepsy including those that were not explicitly explored.
Both distribution-based and anchor-based methods provided evidence to support the ability of the GASE Scale to
detect within-patient change over time in the severity of epilepsy in children. Results indicated a >50% probability of
detecting change and suggests that the GASE Scale is sensitive in detecting change in the severity of epilepsy in children. The relatively low area under the ROC curve might be
attributed to the restrictive definition of “stability” or nonspecific definition of “changed” patients. The results indicate potential for the GASE Scale to discriminate “stable”
and “changed” patients according to select clinical criteria
and to the composite score. However, a more thorough analysis is required to assess other aspects contributing to severity of epilepsy and to establish precise definitions of
stability and change in the clinical criteria as well as in the
GASE Scale.
This study has several strengths. The data derive from a
2-year, multicenter, prospective cohort study with a large
sample size, a strong response rate, and high retention rates.
Participating children were incident cases of epilepsy and
represented diverse types of epilepsy syndromes. Although
the majority of children had less severe epilepsy, the eligibility criteria did not specifically preselect patients of a particular level of severity, and the sample derived from clinics
across the country. The validity of the GASE Scale was
explored with several common statistics used for this purpose and the analyses included an assessment of responsiveness to change using anchor-based and distribution-based
methods. Here the anchor-based method refers to linking
the change in GASE Scale to a meaningful external anchor,
whereas the distribution-based method refers to assessing
responsiveness on the basis of statistically significant
changes of the GASE Scale in relation to the probability that
the change has occurred by chance.15 This will allow for
comparison with other studies and with other scales tested
under similar circumstances.
Our study also has some limitations. Items included in the
HERQULES questionnaires did not allow for comparisons
of the GASE Scale with other common measures of severity
of seizures or syndromes and limited further assessment of
construct validity. In addition, all results pertain to proxy
assessments; only the physicians’ and parents’ perceptions
were evaluated, not the children’s. Validity also varies
according to the population and context. As a result, the
measurement properties of the GASE Scale in this study
may not be applicable to all other situations.16 The minimal
change in the GASE Scale scores that constitutes clinically
Epilepsia, 56(12):1950–1956, 2015
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meaningful changes for patients and physicians was not formally explored. However, other researchers have proposed
that a change of 0.5 in a 7-point Likert scale in various conditions constitutes a minimum clinically important
change.8,17,18 Another proposed metric of clinically important change, with applicability across a broad range of
instruments and conditions, corresponds to “half a standard
deviation” of the instrument’s score.19 For the GASE Scale
(SD = 1.19), this corresponds to 0.6, which is remarkably
similar to the 0.5 proposed by others.
The use of a single-item scale deserves comment. There
are advantages and disadvantages to using single-item global
ratings, as opposed to multi-item questionnaires, to assess
such domains as severity of illness, patient attitudes, or overall satisfaction.3 The literature surrounding the measurement
of severity of epilepsy advocates for a simple, broad, and
flexible instrument that incorporates all of the complex factors affecting severity.1 We espouse the view that a singleitem scale with demonstrated measurement properties can
yield meaningful information and can be used readily in
busy clinical or research settings adding minimal respondent
burden. It is notable that the GASE Scale also provides
information on a domain that is not readily explored by
existing instruments, that is, severity of epilepsy.
Our analyses provide additional evidence to support the
validity of the GASE Scale. Further research will continue
the process of validation, with an emphasis on filling in the
gaps in defining the severity of epilepsy, verifying reliability, comparing the GASE Scale with other epilepsy-related
severity assessment instruments, and identifying minimal
clinically important change. When used together with other
measures of epilepsy and severity, the GASE Scale can provide a more comprehensive evaluation of the multidimensional nature of epilepsy.20,21
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